Cite

HARVARD Citation

    Simões, J. et al. (n.d.). 382PDSecond-line treatment of bevacizumab plus lomustine versus bevacizumab plus irinotecan in patients with recurrent glioblastoma. Annals of oncology. p. . [Online]. 
  
Back to record